A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

NCT01650779 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

BIOLOGICAL: Agalsidase beta

Sponsor

Genzyme, a Sanofi Company